Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
27
8
2022
medline:
15
10
2022
entrez:
26
8
2022
Statut:
ppublish
Résumé
JAK2 inhibitors have changed the therapeutic strategies for the management of primary and secondary myelofibrosis. Ruxolitinib, the first available agent, improved disease-related symptoms, spleen volume, and overall survival compared to conventional chemotherapy. It has been revealed that after 3 years of treatment, about 50% of patients discontinued ruxolitinib for resistance and/or intolerance and should be candidate to a second line of treatment. Second-generation tyrosine kinase inhibitors have been tested in this setting, but all these new drugs do not significantly impact on disease progression. Novel agents are in developments that target on different pathways, alone or in combination with JAK2 inhibitors. In this review, we summarize all the clinical efficacy and safety data of these drugs providing a vision of the possible future.
Identifiants
pubmed: 36017560
doi: 10.1097/CCO.0000000000000898
pii: 00001622-202211000-00019
doi:
Substances chimiques
Nitriles
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
729-737Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2018; 93:1551–1560.
O'Sullivan JM, Harrison CN. Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 2018; 16:121–131.
Price GL, Davis KL, Karve S, et al. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 2014; 9:e90299.
Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 2012; 30:2995–3001.
Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895–2901.
Sokol K, Tremblay D, Bhalla S, et al. Implications of mutation profiling in myeloid malignancies-PART 2 myeloproliferative neoplasms and other myeloid malignancies. Oncology (Williston Park) 2018; 32:e45–e51.
Lataillade JJ, Pierre-Louis O, Hasselbalch HC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008; 112:3026–3035.
Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016; 30:1701–1707.
Verstovsek S, Mesa RA, Gotlib J. et al. investigators C-I. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 2017; 10:55.
Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol 2020; 189:888–903.
Palandri F, Tiribelli M, Breccia M, et al. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: frequency, therapeutic effects, and impact on outcome. Cancer 2021; 127:2657–2665.
Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 2017; 130:1125–1131.
Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13:311–320.
Kesarwani M, Huber E, Kincaid Z, et al. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep 2015; 5:14538.
Pardanani A, Tefferi A, Jamieson C, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofbrosis. Blood Cancer J 2015; 5:e335.
Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv 2020; 4:1792–1800.
Pardanani A, Tefferi A, Masszi T, et al. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol 2021; 195:244–248.
Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, nonrandomised, phase 2, multicentre study. Lancet Haematol 2017; 4:e317–e324.
Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020; 95:594–603.
Harrison CN, Mesa RA, Jamieson C, et al. Case series of potential Wernicke's encephalopathy in patients treated with fedratinib. Blood 2017; 130:4197.
Bassiony S, Harrison CN, McLornan DP. Evaluating the safety, efficacy, and therapeutic potential of momelotinib in the treatment of intermediate/high-risk myelofibrosis: evidence to date. Ther Clin Risk Manag 2020; 16:889–901.
Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23:1441–1445.
Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115:5232–5240.
Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27:1322–1327.
Tefferi A, Barraco D, Lasho TL, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J 2018; 8:29.
Gupta V, Mesa RA, Deininger MW, et al. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 2017; 102:94–102.
Mesa RA, Kiladjian J-J, Catalano JV, et al. SIMPLIFY-1: a Phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor–naïve patients with myelofibrosis. J Clin Oncol 2017; 35:3844–3850.
Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, openlabel, phase 3 trial. Lancet Haematol 2018; 5:e73–81.
Verstovsek S, Chen CC, Egyed M, et al. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 2021; 17:1449–1458.
Jain T, Mesa R. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. Expert Rev Anticancer Ther 2016; 16:1101–1108.
Singer J, Al-Fayoumi S, Ma H, et al. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor,. J Exp Pharmacol 2016; 8:11–19.
Verstovsek S, Odenike O, Scott B, et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood 2009; 114:
Seymour F, To B, Goh A, et al. First report of the Phase-1 study of the novel oral JAK-2 inhibitor SB1518 in patients with myelofibrosis. Haematologica 2010; 95:
Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 2015; 125:2649–2655.
Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 2017; 4:e225–e236.
Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 2018; 4:652–659.
Gerds AT, Savona MR, Scott BL, et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 2020; 4:5825–5835.
Kleppe M, Koche R, Zou L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 2018; 33:29–43.
Talpaz M, Rampal R, Verstovsek S, et al. CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As Monotherapy in Advanced Myelofibrosis Patients Refractory/Intolerant to JAK Inhibitor: Update from Phase 2 MANIFEST Study; Proceedings of the ASH Annual Meeting, Virtual Conference, Held Online; 6 December 2020; Blood 2020; abstract 2163.
Mascarenhas J, Harrison C, Patriarca A, et al. CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, in Combination with Ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis Patients: Update of MANIFEST Phase 2 Study; Proceedings of the ASH Annual Meeting, Virtual Conference, Held Online; 5 December 2020; Blood 2020; abstract 55.
Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118:2069–2076.
Durrant ST, Nagler A, Guglielmelli P, et al. Results from HARMONY: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica 2019; 104:e551–e554.
Yacoub A, Wang E, Rampal R, et al. Addition of parsaclisib, a pi3kdelta inhibitor, in patients (PTS) with suboptimal response to ruxolitinib (RUX): A Phase 2 study in pts with myelofibrosis (MF). 2020 Abstract S216 EHA, EHA Library. 06/12/20; 295036; Hemasphere 2020; 4: abstract 216
Gill H, Yacoub A, Pettit KM, et al. A Phase 2 study of the LSD1 inhibitor Img-7289 (bomedemstat) for the treatment of advanced myelofibrosis ASH abstract 634. Blood 2021; 138: (Supplement 1): 139.
Zefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373:908–919.
Mascarenhas J, Komrokji R, Cavo M, et al. Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor. 2020, ASH, oral session 634, Blood 2020; abstract 53
Al-Ali H, Delgado R, Lange A, et al. KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2I), for myelofibrosis (MF) relapsed or refractory (R/R) to janus-associated kinase inhibitor (JAKI) treatment (TX). 06/12/20 EHA Library. Hemasphere 2020; 4: abstract 215
Petiti J, Lo Iacono M, Rosso V, et al. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. J Cell Mol Med 2020; 24:10978–10986.
Pemmaraju N, Garcia J, Potluri J, et al. The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. 2020, ASH, oral session 634, Blood 2020; abstract 52
Duffield JS, Lupher ML Jr. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect 2010; 23:305–315.
Verstovsek S, Hasserjian RP, Pozdnyakova O, et al. PRM-151 in myelofibrosis: efficacy and safety in an open label extension study. Blood 2018; 132:686.
Pemmaraju N, Gupta V, Ali H, et al. Results from a Phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate, or high risk, relapsed/refractory myelofibrosis. Blood 2019; 134:558.
Mascarenhas J, Kosiorek HE, Varricchio L, et al. Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial 2020, ASH, oral session 634, Blood 2020; abstract 1254.